HRP20210393T1 - Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja - Google Patents
Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja Download PDFInfo
- Publication number
- HRP20210393T1 HRP20210393T1 HRP20210393TT HRP20210393T HRP20210393T1 HR P20210393 T1 HRP20210393 T1 HR P20210393T1 HR P20210393T T HRP20210393T T HR P20210393TT HR P20210393 T HRP20210393 T HR P20210393T HR P20210393 T1 HRP20210393 T1 HR P20210393T1
- Authority
- HR
- Croatia
- Prior art keywords
- seq
- antibody
- humanized anti
- protein
- tfr
- Prior art date
Links
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 12
- 102000004196 processed proteins & peptides Human genes 0.000 claims 12
- 108090000765 processed proteins & peptides Proteins 0.000 claims 12
- 102000007238 Transferrin Receptors Human genes 0.000 claims 3
- 108010033576 Transferrin Receptors Proteins 0.000 claims 3
- 238000010367 cloning Methods 0.000 claims 3
- 239000013599 cloning vector Substances 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical group 0.000 claims 2
- 102000005962 receptors Human genes 0.000 claims 2
- 108020003175 receptors Proteins 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 230000006698 induction Effects 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229940071643 prefilled syringe Drugs 0.000 claims 1
- 231100001258 radiotoxin Toxicity 0.000 claims 1
- 238000011084 recovery Methods 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000012581 transferrin Substances 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/515—Complete light chain, i.e. VL + CL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Transplantation (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Claims (16)
1. Izolirano humanizirano antitijelo anti-transferin receptora (anti-TfR) ili protein s dijelom koji veže antigen humaniziranog anti-TfR antitijela, koje sadrži bilo koji
(a) varijabilni polipeptid teškog lanca koji sadrži HCDR1 iz SEQ ID NO: 1, HCDR2 iz SEQ ID NO: 2, HCDR3 iz SEQ ID NO: 3 i varijabilni polipeptid lakog lanca koji sadrži LCDR1 iz SEQ ID NO: 4, LCDR2 iz SEQ ID NO: 5 i LCDR3 iz SEQ ID NO: 6;
(b) varijabilni polipeptid teškog lanca koji sadrži HCDR1 iz SEQ ID NO: 1, HCDR2 iz SEQ ID NO: 2, HCDR3 iz SEQ ID NO: 3 i varijabilni polipeptid lakog lanca koji sadrži LCDR1 iz SEQ ID NO: 4, LCDR2 iz SEQ ID NO: 8 i LCDR3 iz SEQ ID NO: 6;
(c) varijabilni polipeptid teškog lanca koji sadrži VH SEQ ID NO: 11 i varijabilni polipeptid lakog lanca koji sadrži VL SEQ ID NO: 13;
(d) varijabilni polipeptid teškog lanca koji sadrži VH SEQ ID NO: 11 i varijabilni polipeptid lakog lanca koji sadrži VL SEQ ID NO: 14;
(e) varijabilni polipeptid teškog lanca koji sadrži VH SEQ ID NO: 12 i varijabilni polipeptid lakog lanca koji sadrži VL SEQ ID NO: 13; ili,
(f) varijabilni polipeptid teškog lanca koji sadrži VH iz SEQ ID NO: 12 i varijabilni polipeptid lakog lanca koji sadrži VL iz SEQ ID NO: 14;
pri čemu se navedeno anti-TfR antitijelo ili protein specifično veže na receptor za transferinski receptor (TfR) iz SEQ ID NO: 16.
2. Izolirano humanizirano anti-TfR antitijelo ili protein iz zahtjeva 1, naznačeno time što se navedeno antitijelo ili protein vežu na transferinski receptor s KD od 10 nM ili manje, poželjno s KD od 1 nM ili manje.
3. Izolirano humanizirano anti-TfR antitijelo ili protein prema zahtjevu 1 ili 2, naznačeno time što navedeno antitijelo ili protein induciraju apoptozu stanične linije HL-60 do razine jednake ili veće od razine indukcije odgovarajućeg referentnog himernog antitijela koje ima VH iz SEQ ID NO : 9 i VL iz SEQ ID NO: 10.
4. Izolirano humanizirano anti-TfR antitijelo ili protein prema zahtjevu 1, 2 ili 3, koje obuhvaća konstantnu regiju ljudskog izotipa IgG4, ili mutantnu ili kemijski modificiranu konstantnu regiju, pri čemu navedena mutantna ili kemijski modificirana konstantna regija ne daje ili smanjuje ADCC aktivnost na navedeno antitijelo kada se usporedi s odgovarajućim antitijelom s konstantnom regijom izotipa IgG1 divljeg tipa.
5. Izolirano humanizirano anti-TfR antitijelo ili protein prema zahtjevu 1, 2 ili 3, koje obuhvaća konstantnu regiju humanog IgG1 izotipa, ili mutantnu ili kemijski modificiranu konstantnu regiju, pri čemu navedena mutantna ili kemijski modificirana konstantna regija daje povećanu ADCC aktivnost navedenog antitijela kada se usporedi s odgovarajućim antitijelima s konstantnom regijom izotipa IgG1 divljeg tipa.
6. Izolirano humanizirano anti-TfR antitijelo ili protein prema bilo kojem od zahtjeva 1-5, koji je mAb1 koji sadrži teški lanac iz SEQ ID NO: 18 i laki lanac iz SEQ ID NO: 17.
7. Izolirano humanizirano anti-TfR antitijelo ili protein prema bilo kojem od zahtjeva 1-6, za uporabu (i) kao lijek ili (ii) kao dijagnostika.
8. Izolirano humanizirano anti-TfR antitijelo ili protein prema bilo kojem od zahtjeva 1-6, za uporabu u liječenju tumora, na primjer hematološkog tumora, i preciznije limfoma ili leukemije.
9. Izolirano humanizirano anti-TfR antitijelo ili protein prema bilo kojem od zahtjeva 1-6, za uporabu u liječenju solidnog tumora ili bolesti transplantata naspram domaćina.
10. Farmaceutski pripravak koji sadrži humanizirano anti-TfR antitijelo ili protein prema bilo kojem od zahtjeva 1-9, u kombinaciji s jednim ili više farmaceutski prihvatljivih ekscipijenta, razrjeđivača ili nosača, izborno sadrži i druge aktivne sastojke.
11. Formulacija liofilizata, napunjena štrcaljka ili bočica koja sadrži humanizirano anti-TfR antitijelo ili protein prema bilo kojem od zahtjeva 1-6.
12. Humanizirano anti-TfR antitijelo prema bilo kojem od zahtjeva 1-6, povezano s terapijskim dijelom, na primjer, citotoksinom, lijekom ili radiotoksinom.
13. Vektor kloniranja ili ekspresije za rekombinantnu proizvodnju humaniziranog anti-TfR antitijela prema bilo kojem od zahtjeva 1-6 u stanici domaćina, sadrži barem jednu nukleinsku kiselinu koja kodira navedeno anti-TfR antitijelo.
14. Vektor kloniranja ili ekspresije prema zahtjevu 13, sadrži barem jednu od nukleinskih kiselina koje kodiraju mAb1 kako je definirano u zahtjevu 6.
15. Stanica domaćina koja sadrži vektor kloniranja ili ekspresije prema zahtjevu 13 ili 14.
16. Postupak za proizvodnju humaniziranog anti-TfR antitijela ili proteina prema bilo kojem od zahtjeva 1-6, koji sadrži:
(i) uzgoj stanice domaćina prema zahtjevu 15 za ekspresiju navedenog antitijela ili proteina od strane stanice domaćina; izborno (ii) pročišćavanje navedenog antitijela ili proteina; i, (iii) obnavljanje navedenog antitijela ili proteina.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306192 | 2015-07-22 | ||
| EP16744353.0A EP3325509B1 (en) | 2015-07-22 | 2016-07-21 | Anti-tfr antibodies and their use in treating proliferative and inflammatory disorders |
| PCT/EP2016/067465 WO2017013230A1 (en) | 2015-07-22 | 2016-07-21 | ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20210393T1 true HRP20210393T1 (hr) | 2021-04-30 |
Family
ID=53776520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20210393TT HRP20210393T1 (hr) | 2015-07-22 | 2021-03-08 | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US11230605B2 (hr) |
| EP (1) | EP3325509B1 (hr) |
| JP (1) | JP6858185B2 (hr) |
| KR (1) | KR20180028519A (hr) |
| CN (1) | CN107849136B (hr) |
| AU (1) | AU2016296321B2 (hr) |
| BR (1) | BR112018000650A2 (hr) |
| CA (1) | CA2992509A1 (hr) |
| CY (1) | CY1123941T1 (hr) |
| DK (1) | DK3325509T3 (hr) |
| ES (1) | ES2860988T3 (hr) |
| HK (1) | HK1256088A1 (hr) |
| HR (1) | HRP20210393T1 (hr) |
| HU (1) | HUE053296T2 (hr) |
| IL (1) | IL257065B (hr) |
| LT (1) | LT3325509T (hr) |
| MX (1) | MX2018000569A (hr) |
| PL (1) | PL3325509T3 (hr) |
| PT (1) | PT3325509T (hr) |
| RS (1) | RS61586B1 (hr) |
| RU (1) | RU2737637C2 (hr) |
| SI (1) | SI3325509T1 (hr) |
| WO (1) | WO2017013230A1 (hr) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112017023862A2 (pt) | 2015-05-04 | 2018-07-17 | Cytomx Therapeutics Inc | anticorpos anti-cd71, anticorpos anti-cd71 ativáveis, e métodos de uso destes |
| FR3062213B1 (fr) | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US20210308273A1 (en) | 2018-08-02 | 2021-10-07 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| KR20210081324A (ko) | 2018-08-02 | 2021-07-01 | 다인 세라퓨틱스, 인크. | 근육 표적화 복합체 및 안면견갑상완 근육 이영양증을 치료하기 위한 그의 용도 |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| BR112022014771A2 (pt) * | 2020-01-31 | 2022-10-11 | Dyne Therapeutics Inc | Anticorpo anti-receptor de transferrina (tfr) e usos do mesmo |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11969475B2 (en) * | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11638761B2 (en) * | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| IL311175A (en) | 2021-09-01 | 2024-04-01 | Biogen Ma Inc | Anti-transferrin receptor antibodies and their uses |
| TW202330601A (zh) * | 2021-09-13 | 2023-08-01 | 德州大學系統董事會 | ＴｆＲ抗原結合蛋白及其用途 |
| US11931421B2 (en) * | 2022-04-15 | 2024-03-19 | Dyne Therapeutics, Inc. | Muscle targeting complexes and formulations for treating myotonic dystrophy |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
| ES2694002T3 (es) * | 1999-01-15 | 2018-12-17 | Genentech, Inc. | Polipéptido que comprende una región Fc de IgG1 humana variante |
| EP2357006B1 (en) | 2002-07-31 | 2015-09-16 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| WO2005011082A2 (en) | 2003-07-23 | 2005-02-03 | Univeral Infusion Technology | Drive motor transmission system |
| PT1740616E (pt) * | 2004-04-30 | 2012-03-23 | Inst Nat Sante Rech Med | Anticorpo anti-rtf |
| EP1765868B1 (en) * | 2004-06-07 | 2016-04-20 | MacroGenics, Inc. | Transferrin receptor antibodies |
| CA2970873C (en) * | 2005-05-09 | 2022-05-17 | E. R. Squibb & Sons, L.L.C. | Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics |
| FR2953841B1 (fr) * | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| JP2015524816A (ja) * | 2012-08-02 | 2015-08-27 | アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル | サラセミアを処置するためのトランスフェリンレセプターアンタゴニストの使用 |
| CN104797600A (zh) * | 2012-11-08 | 2015-07-22 | 国立大学法人宫崎大学 | 能够特异性识别转铁蛋白受体的抗体 |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
-
2016
- 2016-07-21 HU HUE16744353A patent/HUE053296T2/hu unknown
- 2016-07-21 WO PCT/EP2016/067465 patent/WO2017013230A1/en active Application Filing
- 2016-07-21 LT LTEP16744353.0T patent/LT3325509T/lt unknown
- 2016-07-21 KR KR1020187004745A patent/KR20180028519A/ko not_active Application Discontinuation
- 2016-07-21 CA CA2992509A patent/CA2992509A1/en active Pending
- 2016-07-21 RU RU2018106364A patent/RU2737637C2/ru active
- 2016-07-21 US US15/746,590 patent/US11230605B2/en active Active
- 2016-07-21 BR BR112018000650A patent/BR112018000650A2/pt active Search and Examination
- 2016-07-21 SI SI201631117T patent/SI3325509T1/sl unknown
- 2016-07-21 EP EP16744353.0A patent/EP3325509B1/en active Active
- 2016-07-21 DK DK16744353.0T patent/DK3325509T3/da active
- 2016-07-21 PL PL16744353T patent/PL3325509T3/pl unknown
- 2016-07-21 CN CN201680040714.2A patent/CN107849136B/zh active Active
- 2016-07-21 JP JP2018522867A patent/JP6858185B2/ja active Active
- 2016-07-21 IL IL257065A patent/IL257065B/en unknown
- 2016-07-21 MX MX2018000569A patent/MX2018000569A/es unknown
- 2016-07-21 RS RS20210280A patent/RS61586B1/sr unknown
- 2016-07-21 ES ES16744353T patent/ES2860988T3/es active Active
- 2016-07-21 PT PT167443530T patent/PT3325509T/pt unknown
- 2016-07-21 AU AU2016296321A patent/AU2016296321B2/en active Active
-
2018
- 2018-11-27 HK HK18115150.4A patent/HK1256088A1/zh unknown
-
2021
- 2021-03-08 HR HRP20210393TT patent/HRP20210393T1/hr unknown
- 2021-03-09 CY CY20211100200T patent/CY1123941T1/el unknown
- 2021-12-09 US US17/546,208 patent/US20220119543A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20190092870A1 (en) | 2019-03-28 |
| EP3325509A1 (en) | 2018-05-30 |
| RU2018106364A (ru) | 2019-08-22 |
| CY1123941T1 (el) | 2022-05-27 |
| AU2016296321A1 (en) | 2018-01-25 |
| HK1256088A1 (zh) | 2019-09-13 |
| CN107849136A (zh) | 2018-03-27 |
| RU2737637C2 (ru) | 2020-12-01 |
| IL257065A (en) | 2018-03-29 |
| RU2018106364A3 (hr) | 2019-08-22 |
| CN107849136B (zh) | 2022-04-01 |
| DK3325509T3 (da) | 2021-03-08 |
| HUE053296T2 (hu) | 2021-06-28 |
| US20220119543A1 (en) | 2022-04-21 |
| RS61586B1 (sr) | 2021-04-29 |
| BR112018000650A2 (pt) | 2018-09-18 |
| AU2016296321B2 (en) | 2022-09-08 |
| US11230605B2 (en) | 2022-01-25 |
| IL257065B (en) | 2022-07-01 |
| JP2018521691A (ja) | 2018-08-09 |
| PT3325509T (pt) | 2021-03-12 |
| JP6858185B2 (ja) | 2021-04-14 |
| ES2860988T3 (es) | 2021-10-05 |
| KR20180028519A (ko) | 2018-03-16 |
| LT3325509T (lt) | 2021-06-10 |
| EP3325509B1 (en) | 2020-12-16 |
| WO2017013230A1 (en) | 2017-01-26 |
| CA2992509A1 (en) | 2017-01-26 |
| MX2018000569A (es) | 2018-09-27 |
| SI3325509T1 (sl) | 2021-07-30 |
| PL3325509T3 (pl) | 2021-07-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20210393T1 (hr) | Anti-tfr antitijela i njihova uporaba u liječenju proliferativnih i upalnih poremećaja | |
| JP6923602B2 (ja) | 抗アクチビンａ抗体及びその使用 | |
| JP2018521691A5 (hr) | ||
| ES2888224T3 (es) | Anticuerpos humanos contra PD-1 | |
| CN110041429B (zh) | 抗cd-3抗体，与cd3及cd20结合的双特异性抗原结合分子，及其用途 | |
| JP7118135B2 (ja) | ＧＡＲＰ－ＴＧＦ－β抗体 | |
| RU2018119165A (ru) | Антитело против лиганда 1 запрограммированной гибели клеток (pd-l1), его антигенсвязывающий фрагмент и их медицинское применение | |
| CA3034849A1 (en) | Anti-pd1 monoclonal antibody, pharmaceutical composition thereof and use thereof | |
| JP2018534933A5 (hr) | ||
| JP2017532037A5 (hr) | ||
| JP2017507954A5 (hr) | ||
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| AU2018206531A1 (en) | Human antibodies to S. aureus Hemolysin A toxin | |
| HRP20171775T1 (hr) | Molekule protutijela koje vežu trombin i njihova uporaba | |
| JP2018510617A5 (hr) | ||
| RU2020127196A (ru) | Антитело против 4-1bb, его антигенсвязывающий фрагмент и его медицинское применение | |
| AU2015254498A1 (en) | Anti-human VEGF antibodies with unusually strong binding afinity to human VEGF-A and cross reactivity to human VEGF-B | |
| BR112020020637A2 (pt) | anticorpo anti-pd-l1, fragmento de ligação ao antígeno ou variante do mesmo, anticorpo biespecífico, composição farmacêutica e uso dos mesmos para aliviar ou tratar tumores | |
| RU2019104980A (ru) | Анти-icos антитела | |
| JP2015501830A5 (hr) | ||
| RU2015108797A (ru) | Антитела к jagged и способы их применения перекрестная ссылка на родственные заявки | |
| US11713357B2 (en) | CD38 protein antibody and application thereof | |
| JP2020522281A5 (hr) | ||
| JP2020522280A5 (hr) | ||
| HRP20220197T1 (hr) | Antitijela protiv il-22r |